Apnimed, Inc. APMD
IPO $25.69 -$2.25-8.05% NASDAQ
IPO Score
IPO Date
Jul 30, 2026
Recommendation
Dividend Power Score
Prev Close
Volume
Avg Vol (90D)
--
Market Cap
Dividend & Yield
--
52-Week Range
P/E (TTM)
EPS (TTM)
Corporate Info
Phone Number
(617) 500-8880
Address
39 John F. Kennedy Street
4th Floor
Cambridge, MA 02138
Country
United States
Year Founded
2017
Details
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Employees
65
Business Description
Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. Its products include AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.